Overview

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Status:
Completed
Trial end date:
2018-03-20
Target enrollment:
Participant gender:
Summary
Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.
Phase:
Phase 1
Details
Lead Sponsor:
Esanex Inc.
Treatments:
Everolimus
Sirolimus